Evidence map›Paper›PMID 40290511›Full record

ReviewTherapeutic advances in drug safety2025

Perspective review: Will generative AI make common data models obsolete in future analyses of distributed data networks?

Jeffery L Painter, Darmendra Ramcharran, Andrew Bate

Abstract readReview
In one paragraph

Review in Therapeutic advances in drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. How is AI developing in pharmacovigilance?Therapeutic advances in drug safety · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jeffery L PainterGSK, 410 Blackwell Street, Durham, NC 27701, USA.ORCID https://orcid.org/0000-0001-9651-9904
Darmendra RamcharranGSK, Providence, RI, USA.
Andrew BateGSK, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Integrating real-world healthcare data is challenging due to diverse formats and terminologies, making standardization resource-intensive. While Common Data Models (CDMs) facilitate interoperability, they often cause information loss, exhibit semantic inconsistencies, and are labor-intensive to implement and update. We explore how generative artificial intelligence (GenAI), especially large language models (LLMs), could make CDMs obsolete in quantitative healthcare data analysis by interpreting natural language queries and generating code, enabling direct interaction with raw data. Knowledge graphs (KGs) standardize relationships and semantics across heterogeneous data, preserving integrity. This perspective review proposes a fourth generation of distributed data network analysis, building on previous generations categorized by their approach to data standardization and utilization. It emphasizes the potential of GenAI to overcome the limitations CDMs with GenAI-enabled access, KGs, and automatic code generation. A data commons may further enhance this capability, and KGs may well be needed to enable effective GenAI. Addressing privacy, security, and governance is critical; any new method must ensure protections comparable to CDM-based models. Our approach would aim to enable efficient, real-time analyses across diverse datasets and enhance patient safety. We recommend prioritizing research to assess how GenAI can transform quantitative healthcare data analysis by overcoming current limitations.

Indexed as

Common Data Model (CDM)distributed data networkdrug safetygenerative AIpharmacovigilance

Identifiers

PMID40290511
PMCPMC12033412

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.